深在性真菌症患者に対するitraconazole注射薬およびカプセル薬順次投与の有効性

DOI 被引用文献5件 参考文献10件

書誌事項

タイトル別名
  • Efficacy and safety of Itraconazole injections and capsules in deep mycosis uncontrolled multicenter open-label trial
  • Itraconazole-Deep Mycosis Research Group
  • Itraconazole深在性真菌症研究班

この論文をさがす

抄録

We investigated the efficacy and safety of Itraconazole (ITCZ) in patients with deep mycosis, evaluating intravenous injection of ITCZ (200 mg) for 2 weeks (twice a day for the first two days, then once a day for the remaining 12 days) prior to the oral administration of ITCZ capsules (200 mg) twice a day.<BR>Total efficacy was 67.7%(21/31 cases). The efficacy in aspergillosis patients was 57.9%(11/19 cases), 71.4%(5/7) in candidiasis patients, and 100%(5/5) in cryptococcosis patients. No difference was seen in the incidence of adverse events in injection and capsule administration, and most observed adverse events of ITCZ were already known.<BR>ITCZ plasma trough concentration after two days of injection (200 mg twice a day) reached a level (811.3±316.0 ng/mL, Mean ± S. D., n=42) efficient in treating conditions caused by primary underlying mycoses (Aspergillus, Candida, Cryptococcus), and high plasma was maintained continuously through administration of ITCZ capsules.<BR>ITCZ injection reaches efficient plasma concentration rapidly compared to ITCZ capsules. ITCZ injection is effective for serious and acute conditions but the approved maximum dose of 200 mg/day for ITCZ capsules is not effective in treating deep mycosis.<BR>Plasma concentration reached by ITCZ injection is continuously maintained through the administration of ITCZ capsules (200 mg, twice a day). We concluded that the first 2 weeks of injection prior to oral administration is effective in treating deep mycosis.

収録刊行物

被引用文献 (5)*注記

もっと見る

参考文献 (10)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ